Established in 2011, Shanghai YaKe Biotechnology Co Ltd. is headquartered in the Wanggu Science and Technology Park in Yangpu District, Shanghai. Committed to the mission of "innovation powering healthcare," Jaico Biotechnology continually advances its research and development efforts. This enables the company to consistently expand its portfolio of novel cancer immunotherapy technologies, effectively constructing an arsenal of cutting-edge treatments in the realm of tumor cell immunotherapy.

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

CAR-T

Autologous CAR-T

Universal CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	35
Hemic and Lymphatic Diseases	27
Immune System Diseases	20
Nervous System Diseases	1
Infectious Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

CAR-T	25
Autologous CAR-T	9
Universal CAR-T	1
Hematopoietic stem cell therapy	1

Top 5 Target	Count

GPRC5D(G-protein coupled receptor family C group 5member D)	1
EphA2(Ephrin type-A receptor 2)	1
EGFRvIII(Epidermal growth factor receptor variant III)	1
APRIL(Tumor necrosis factor ligand superfamily member 13)	1
CD5(T-cell surface glycoprotein CD5)	1

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 15 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1

Phase 2

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Anti BCMA CART cell therapy(Shanghai YaKe Biotechnology Co Ltd) ( 4-1BB x BCMA )	Multiple Myeloma More	Phase 2
GPRC5D CAR-T(Shanghai YaKe Biotechnology) ( GPRC5D )	Multiple Myeloma More	Phase 2
APRIL-BAFF-Bicephali CAR-T cells(Yake Biotechnology) ( APRIL x BAFF-R )	Refractory Multiple Myeloma More	Phase 1/2
GD2/B7H3 CAR T-cell therapy(Yake Biotechnology) ( CD276 x GD2 )	Desmoplastic Small Round Cell Tumor More	Phase 1/2
Anti CD22 CAR-T cell therapy (YaKe Biotech) ( CD22 )	Acute Lymphoblastic Leukemia More	Phase 1

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis